Flagship Biosciences and Genomenon Partner to Advance Precision Medicine Development

Broomfield, CO and Ann Arbor, MI – February 7, 2023 – Flagship Biosciences, a leader in spatial biology and biomarker analytics services, today announced a strategic partnership with Genomenon® that aims to transform the drug development paradigm with accelerated biomarker discovery and companion diagnostics development solutions.

Flagship Biosciences has long been recognized for its innovative spatial biology services, fueled by AI image analysis technology that improves the accuracy of tissue-based pathology. With its recent acquisition of Interpace Pharma Solutions, Flagship has expanded its portfolio to include proven cytogenetic, molecular pathology and genomic profiling solutions. By partnering with Genomenon, the company will further enrich its genomic profiling capabilities with the unparalleled breadth of published clinical genomic evidence only available in the Genomenon Mastermind™ knowledgebase.

Through its AI-driven genomics platform, Genomenon delivers disease-specific genomic datasets that identify the most comprehensive set of causative variants for a specific disease. These troves of rich genomic information—known as variant landscapes—will complement Flagship Biosciences’ work by accelerating its assay development, validation, and deployment services that support precision medicine drug trials, biomarker discovery, and companion diagnostic development. As a result, this partnership will further enhance new genomic profiling services for biomarker characterization and improved patient stratification for clinical trials and treatment selection.

“This partnership marks an important milestone for our company,” said Flagship Biosciences CEO Trevor Johnson. “By leveraging Genomenon’s cutting-edge technology and expertise, we will be able to deliver genomic profiling services that are even more precise, providing unparalleled insights into biomarker characterization and optimal patient stratification for clinical trials and treatment selection.”

“Flagship Biosciences’ biomarker data services are critical to informing precision medicine decisions, and together with Genomenon’s disease-specific genomic datasets powered by the Mastermind knowledgebase, the two companies provide unique insight to improve the clinical trial process,” said Mike Klein, Genomenon CEO. “Through this partnership, Genomenon will enable the Flagship scientific team to provide their customers with extensive, previously unidentified variant information—giving patients quicker access to life-saving treatments.”

About Flagship Biosciences
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success. For more information, please visit flagshipbio.com and follow us on Twitter and LinkedIn.

About Genomenon
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.

Learn more about Genomenon at genomenon.com and follow them on LinkedIn and Twitter.